Bridging treatment before autologous transplantation

8 evidence topics · 2 sources

Objective

Bridging-treatment report

“We herein report a case of relapsed primary DLBCL of the CNS complicated with primary biliary cholangitis, cirrhosis, and pancytopenia that was successfully treated with bridging therapy with tirabrutinib before autologous hematopoietic stem cell transplantation (ASCT).” (opens the source at this quote in a new tab)

Location and study date

Institution

“Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan” (opens the source at this quote in a new tab)

Study design

Eligibility criteria

Not applicable.

Treatment

Treatment and dosage

“She received tirabrutinib and intravitreal methotrexate for relapsed disease.” (opens the source at this quote in a new tab)
“Her starting dose of tirabrutinib was 320 mg once a day, and she continued the same dose.” (opens the source at this quote in a new tab)

Study outcomes

Rationale for using clinical response as an observed outcome

Not applicable.

Statistical analysis description

Number of participants (Planned and analyzed)

Description of analysis sets

Not applicable.

Results

Participant disposition

Post-transplant engraftment

“Neutrophil engraftment occurred on day 13.” (opens the source at this quote in a new tab)

Baseline characteristics

Age, presentation, and comorbidities

“A 53-year-old woman was referred to our hospital with a chief complaint of dizziness.” (opens the source at this quote in a new tab)
“She had PBC, cirrhosis (Child-Pugh A), and pancytopenia due to hypersplenism as comorbidity.” (opens the source at this quote in a new tab)

Efficacy results

Response before and after transplantation

“Her brain lesion was ameliorated after four weeks of tirabrutinib.” (opens the source at this quote in a new tab)
“No relapse of her lymphoma was noted during the follow-up period of 6 months after ASCT.” (opens the source at this quote in a new tab)

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

Reported post-transplant safety

“Veno-occlusive disease/sinusoidal obstruction syndrome did not occur.” (opens the source at this quote in a new tab)

Study limitations

Summary

This report concerns one participant who received tirabrutinib together with intravitreal methotrexate and subsequently underwent autologous transplantation. The post-transplant absence of relapse cannot be attributed to tirabrutinib alone. A tolerated 320 mg daily dose in this case does not establish a dosing regimen for other participants with cirrhosis.